The Efficacy And Prognosis Assessment Of Serum Tumor Markers In NSCLC Treated With Erlotinib

Purpose1. The relationship between serum markers CEA, NSE, Cyfra21-1and clinic-pathological factors in patients of NSCLC.2. The relationship between serum markers CEA, NSE, Cyfra21-1and therapy efficacy, prognosis in NSCLC treated with erlotinib.3. The relationship between decrease of serum markers CEA, NSE, Cyfra21-1and therapy efficacy, prognosis in NSCLC treated with erlotinib.MethodReview the patients of NSCLC treated with erlotinib during the period of2011-2012in Shandong Tumor Hospital, collect the basic clinic-pathological and test results of serum CEA, NSE and Cyfra21-1before the treatment, one month later and three months later. Evaluate the therapeutic effect by imaging examination, follow-up every patient to get their lifetime. At last, analysis all dates by Statistical Methods.Result1. The relationship between serum markers and clinic-pathological factors, efficacy.Average value of CEA in patients over60years old is higher than that in patients less than60years old(19.38vs12.40, P=0.33). The CEA levels of non-smokers were higher than smokers(18.75vs11.00, P=0.23). NSE levels were higher in non-smokers than smokers (16.67vs8.67, P=0.014). Devide the patients into two parts by the average value43.93of CEA, the objective response rate were higher in patients with high CEA levels than the others (P=0.023)2. The relationship between the decline of tumor markers and efficacy.According to the average value of the decline of CEA in one month23.13and three month20.29, better ORR was observed in patients whose CEA declined more one month after the beginning of erlotinib treatment (P=0.05). The DCR in patients whose CEA decreased more in both one and three months later were higher than that in other patients (P=0.00)3. The relationship between the decline of tumor marker and lifetime.The lifetime in patients with high CEA before erlotinib treatment is significantly longer than that in other patients (14.77vs8.23, P=0.028). One month after erlotinib treatment, the patients whose CEA decline more gain much longer lifetime (10.13vs4.00, P=0.002). Three months after erlotinib treatment, the lifetime in patients with significantly decline of CEA are much longer than lifetime in other patients (7.5vs3.5, P=0.04),so was the NSE (6.71vs2.67, P=0.02)ConclusionErlotinib show a good effect in targeted therapy of NSCLC. The levels of serum tumor markers CEA, NSE and Cyfra21-1before erlotinib treatment and the decrease levels after erlotinib treatment can be used to predict and monitor treatment efficacy in patients with NSCLC, predict the prognosis of patients as well.